COR Therapeutics, Inc. Announces Appointment of Chief Financial Officer.Health/Medical Editors SOUTH SAN FRANCISCO--(BW HealthWire)--June 22, 2000 COR Therapeutics, Inc. (Nasdaq:CORR CORR Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51. ) announced today the promotion of Peter S. Roddy to Senior Vice President, Finance and Chief Financial Officer. Previously, Mr. Roddy served as Vice President, Finance of COR. Mr. Roddy will be a member of the Company's Executive Committee and will report to the President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Vaughn M. Kailian. As Senior Vice President, Finance and Chief Financial Officer, Mr. Roddy will be responsible for Finance, Information Systems, Investor Relations Investor relations The process by which the corporation communicates with its investors. , and Facilities and Operations. Prior to joining COR in 1990 as Controller, Mr. Roddy, age 40, held a variety of positions at Price Waterhouse & Company, Hewlett Packard Company and MCM (MultiChip Module or MicroChip Module) A chip package that contains several bare chips mounted close together on a substrate (base) of some kind. Laboratories, Inc. Mr. Roddy received his B.S. in Business Administration from the University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal . COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· , deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. and restenosis. For additional information about COR Therapeutics, please visit the Company's Web site at http://www.corr.com. In addition to the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Actual results of the Company's activities may differ significantly from the potential results discussed in such forward-looking statements. These forward-looking statements are based on current expectations and the Company assumes no obligation to update this information. A full discussion of COR Therapeutics' operations and financial condition, and specific factors that could cause the Company's actual performance to differ from current expectations, can be found in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-Q for the quarter ended March 31, 2000, and Report on Form 10-K for the year ended December 31, 1999. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion